Digital PCR (dPCR) and Real-Time PCR (qPCR)

Digital PCR (dPCR) and Real-time PCR (qPCR) Market is expected to grow with a CAGR of 8.80% from 2022 to 2028

  • Digital PCR (dPCR) and Real-Time PCR (qPCR) Market

As stated by our extensive report, providing insights on Type and Applications, the global 3D Printing Ceramic market accounted for 8,860.22 USD Million in 2020.

Digital PCR counts individual molecules for absolute quantification. Digital PCR works by digitizing a sample into many individual real-time PCR reactions; some portions of these micro-reactions contain the target molecule (positive) while others do not (negative).

Adoption of these technologies helps to measure small variants within the genetic material. Although real-time PCR is a great technique, digital PCR offers an absolute measure of target nucleic acid molecules. Determinants such as the rising incidence of infectious diseases; the rising number of CRO, forensic, and other research laboratories; and technological advancement in PCR are driving the growth in the market. Moreover, developing opportunities from Asian nations and transition to genome-based from plant drug discovery will provide huge opportunities for Digital PCR (dPCR) and Real-time PCR (qPCR) market in the forecast period. Whereas, technical limitations related to PCR and the huge cost of PCR equipment are likely to restrict the market growth.

Innovations inplant-centric proteinshave resulted in a positive influence on the growth of meat substitute goods. Manufacturers are introducing plant-centric ingredients to produce meat substitutes, which has gained extensive acceptance among customers. According to the European Regional Development Fund, 22% of UK consumers convey that they consume more protein from other sources rather than meat. For the millennials and iGeneration, the numbers have increased to 25%, indicating the high growth of the protein alternatives market in the country. This factor helps in a positive manner for this market owing to the changing consumer choices and the high adaptability among consumers. The rising investments made by ingredient producers are propelling the market growth.

North America is the largest market. This is attributed to a rise in illness incidence and the number of Hepatitis, HIV, viral infections including cancer, and helicobacter pylori infection cases.

The expansion of infrastructure in healthcare, lower procedural costs for dPCR and qPCR-centric illness diagnostics, and a rise in healthcare expenditure are all driving the market forward. The rising healthcare infrastructure in developing nations is accompanied by the swift upgrading of healthcare facilities. This is contributing to diagnostic laboratories’ rising demand for clinical diagnostic methods, which is leading to huge sales of clinical dPCR and qPCR goods. Furthermore, expanded investments whether public or private to enhance illness diagnostics awareness and for the introduction of technologically sophisticated products are augmenting the Digital PCR (dPCR) and Real-time PCR (qPCR) Market forward.

However, the huge cost of instruments related to dPCR and cons in dPCR and qPCR methods are projected to hamper the Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market growth. To attain the intended process output, PCR analysis is performed using dPCR devices to concatenate various scientific technologies (microfluidics, nanofabrication, and PCR). These instruments are compact, with short cycle times.

Some of the prominent players operating in the GlobalDigital PCR (dPCR) and Real-time PCR (qPCR) Marketare Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland), Abbott Laboratories (US), Agilent Technologies (US), Analytik Jena AG (Switzerland), Becton Dikinson and Company (US), bioMérieux SA (France), Danaher Corporation (US), Eppendorf (Germany), Fluidigm Corporation (US), Merck KGaA (Germany), QIAGEN N.V. (Netherlands), Takara Bio (Japan), Meridian Bioscience (US), Promega Corporation (US), Enzo Life Sciences, Inc. (US), Bioneer (South Korea), ELITech Group (France), and Quidel Corporation (US)..